Significant Economic Benefits of mRNA Cancer Vaccines Currently Under Development Eugene/Getty Images
In August 2025, the United States announced a $500 million cut in funding for vaccine development, jeopardizing the potential advantages of mRNA cancer vaccine research. According to Alison Galvani from Yale University and colleagues, this reduction poses significant risks to future developments.
The team’s analysis indicates that the treatment advancements observed in current clinical trials could prevent nearly 50,000 deaths, translating to an economic value of $75 billion. “This estimate is based on just one annual cohort of patients for each cancer type,” stated the researchers.
Experts caution that diminishing federal investment in mRNA vaccine technology risks undermining these crucial benefits.
Recent research highlights that many of the most effective cancer treatments leverage the body’s immune response to combat tumors. mRNA vaccines can specifically activate the immune system to identify proteins unique to cancer cells, offering a tailored approach to cancer treatment.
To evaluate the potential impact of these vaccines, Galvani and her team analyzed 32 ongoing mRNA cancer vaccine clinical trials in the U.S. They identified the top 11 promising trials and estimated the additional years of life these treatments could provide if widely administered to eligible patients within a year.
Furthermore, the researchers calculated the annual value of an additional year of life, utilizing statistical measures regarding how much individuals would pay for such benefits. They applied values established by the U.S. Department of Health and Human Services to assess the implications of potential regulatory shifts.
Although the annual estimates may be optimistic—given that some vaccine candidates may not gain approval—Oliver Watson from Imperial College London employed a similar framework, estimating that COVID-19 vaccines have yielded global health and economic benefits ranging from $5 trillion to $38 trillion.
If researchers evaluated the cumulative value of multiple cohorts receiving cancer treatments and extended their analysis over a longer time frame, the potential benefits would be substantially greater. “These estimates are undoubtedly conservative,” Watson notes.
Topics:
Source: www.newscientist.com
